Small Particle DEBIRI TACE as Salvage Therapy in Patients with Liver Dominant Colorectal Cancer Metastasis: Retrospective Analysis of Safety and Outcomes
The aim of this study was to examine the safety and efficacy of 40 µm and 75 µm calibrated irinotecan-eluting beads (DEBIRI-TACE) for the treatment of colorectal cancer metastases. We conducted a retrospective review of 36 patients with unresectable liver metastases from colorectal cancer who were t...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-01-01
|
| Series: | Current Oncology |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1718-7729/29/1/20 |
| _version_ | 1827666030708654080 |
|---|---|
| author | Nicolas Voizard Tiffany Ni Alex Kiss Robyn Pugash Michael Jonathon Raphael Natalie Coburn Elizabeth David |
| author_facet | Nicolas Voizard Tiffany Ni Alex Kiss Robyn Pugash Michael Jonathon Raphael Natalie Coburn Elizabeth David |
| author_sort | Nicolas Voizard |
| collection | DOAJ |
| description | The aim of this study was to examine the safety and efficacy of 40 µm and 75 µm calibrated irinotecan-eluting beads (DEBIRI-TACE) for the treatment of colorectal cancer metastases. We conducted a retrospective review of 36 patients with unresectable liver metastases from colorectal cancer who were treated with DEBIRI-TACE between 2017 to 2020. Patients who received at least one session of DEBIRI were included in our analysis. A total of 105 DEBIRI sessions were completed. 86% of patients (<i>n</i> = 31) underwent one round of treatment, 14% of patients (<i>n</i> = 5) underwent two distinct rounds of treatment. The majority of patients were discharged the next day (92%, <i>n</i> = 33 patients) with no 30-day post-DEBIRI mortality. Five high-grade adverse events occurred, including longer stay for pain management (<i>n</i> = 2), postembolization syndrome requiring readmission (<i>n</i> = 2), and liver abscess (<i>n</i> = 1). The average survival from diagnosis of metastatic disease was 33.3 months (range 11–95, median 28). Nine of 36 patients are still alive (December 2020) and have an average follow-up time of 36.8 months from T0 (range 12–63, median 39). Small particle DEBIRI is safe and well-tolerated in the salvage setting, with outcomes comparable to that of larger bead sizes. |
| first_indexed | 2024-03-10T01:40:15Z |
| format | Article |
| id | doaj.art-48f75500e32e4874a1227d45b0dad0c6 |
| institution | Directory Open Access Journal |
| issn | 1198-0052 1718-7729 |
| language | English |
| last_indexed | 2024-03-10T01:40:15Z |
| publishDate | 2022-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Current Oncology |
| spelling | doaj.art-48f75500e32e4874a1227d45b0dad0c62023-11-23T13:25:56ZengMDPI AGCurrent Oncology1198-00521718-77292022-01-0129120922010.3390/curroncol29010020Small Particle DEBIRI TACE as Salvage Therapy in Patients with Liver Dominant Colorectal Cancer Metastasis: Retrospective Analysis of Safety and OutcomesNicolas Voizard0Tiffany Ni1Alex Kiss2Robyn Pugash3Michael Jonathon Raphael4Natalie Coburn5Elizabeth David6Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON M4N 3M5, CanadaOdette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON M4N 3M5, CanadaOdette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON M4N 3M5, CanadaOdette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON M4N 3M5, CanadaOdette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON M4N 3M5, CanadaOdette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON M4N 3M5, CanadaOdette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON M4N 3M5, CanadaThe aim of this study was to examine the safety and efficacy of 40 µm and 75 µm calibrated irinotecan-eluting beads (DEBIRI-TACE) for the treatment of colorectal cancer metastases. We conducted a retrospective review of 36 patients with unresectable liver metastases from colorectal cancer who were treated with DEBIRI-TACE between 2017 to 2020. Patients who received at least one session of DEBIRI were included in our analysis. A total of 105 DEBIRI sessions were completed. 86% of patients (<i>n</i> = 31) underwent one round of treatment, 14% of patients (<i>n</i> = 5) underwent two distinct rounds of treatment. The majority of patients were discharged the next day (92%, <i>n</i> = 33 patients) with no 30-day post-DEBIRI mortality. Five high-grade adverse events occurred, including longer stay for pain management (<i>n</i> = 2), postembolization syndrome requiring readmission (<i>n</i> = 2), and liver abscess (<i>n</i> = 1). The average survival from diagnosis of metastatic disease was 33.3 months (range 11–95, median 28). Nine of 36 patients are still alive (December 2020) and have an average follow-up time of 36.8 months from T0 (range 12–63, median 39). Small particle DEBIRI is safe and well-tolerated in the salvage setting, with outcomes comparable to that of larger bead sizes.https://www.mdpi.com/1718-7729/29/1/20transarterial chemoembolizationcolorectal cancerdrug eluting beads with irinotecan |
| spellingShingle | Nicolas Voizard Tiffany Ni Alex Kiss Robyn Pugash Michael Jonathon Raphael Natalie Coburn Elizabeth David Small Particle DEBIRI TACE as Salvage Therapy in Patients with Liver Dominant Colorectal Cancer Metastasis: Retrospective Analysis of Safety and Outcomes Current Oncology transarterial chemoembolization colorectal cancer drug eluting beads with irinotecan |
| title | Small Particle DEBIRI TACE as Salvage Therapy in Patients with Liver Dominant Colorectal Cancer Metastasis: Retrospective Analysis of Safety and Outcomes |
| title_full | Small Particle DEBIRI TACE as Salvage Therapy in Patients with Liver Dominant Colorectal Cancer Metastasis: Retrospective Analysis of Safety and Outcomes |
| title_fullStr | Small Particle DEBIRI TACE as Salvage Therapy in Patients with Liver Dominant Colorectal Cancer Metastasis: Retrospective Analysis of Safety and Outcomes |
| title_full_unstemmed | Small Particle DEBIRI TACE as Salvage Therapy in Patients with Liver Dominant Colorectal Cancer Metastasis: Retrospective Analysis of Safety and Outcomes |
| title_short | Small Particle DEBIRI TACE as Salvage Therapy in Patients with Liver Dominant Colorectal Cancer Metastasis: Retrospective Analysis of Safety and Outcomes |
| title_sort | small particle debiri tace as salvage therapy in patients with liver dominant colorectal cancer metastasis retrospective analysis of safety and outcomes |
| topic | transarterial chemoembolization colorectal cancer drug eluting beads with irinotecan |
| url | https://www.mdpi.com/1718-7729/29/1/20 |
| work_keys_str_mv | AT nicolasvoizard smallparticledebiritaceassalvagetherapyinpatientswithliverdominantcolorectalcancermetastasisretrospectiveanalysisofsafetyandoutcomes AT tiffanyni smallparticledebiritaceassalvagetherapyinpatientswithliverdominantcolorectalcancermetastasisretrospectiveanalysisofsafetyandoutcomes AT alexkiss smallparticledebiritaceassalvagetherapyinpatientswithliverdominantcolorectalcancermetastasisretrospectiveanalysisofsafetyandoutcomes AT robynpugash smallparticledebiritaceassalvagetherapyinpatientswithliverdominantcolorectalcancermetastasisretrospectiveanalysisofsafetyandoutcomes AT michaeljonathonraphael smallparticledebiritaceassalvagetherapyinpatientswithliverdominantcolorectalcancermetastasisretrospectiveanalysisofsafetyandoutcomes AT nataliecoburn smallparticledebiritaceassalvagetherapyinpatientswithliverdominantcolorectalcancermetastasisretrospectiveanalysisofsafetyandoutcomes AT elizabethdavid smallparticledebiritaceassalvagetherapyinpatientswithliverdominantcolorectalcancermetastasisretrospectiveanalysisofsafetyandoutcomes |